Accelerate Diagnostics (Nasdaq:AXDX) - Hisse Senedi Fiyatı, Haberler ve Analizler

AXDX Stoklara Genel Bakış

Bir in vitro diagnostik şirketi olan Accelerate Diagnostics, Inc. Amerika Birleşik Devletleri, Avrupa ve Orta Doğu'da ciddi enfeksiyonların teşhisine yönelik çözümler sunmaktadır.

Şirket hakkında

AXDX temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 9.1% oranında arttı

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Negatif hissedar öz sermayesi

Anlamlı bir piyasa değeri yok ( $44M )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

Accelerate Diagnostics, Inc. Rakipler

Apyx Medical

NasdaqGS:APYX

US$43.3m

Medinotec

OTCPK:MDNC

US$58.7m

DIH Holding US

NasdaqGM:DHAI

US$49.1m

Milestone Scientific

NYSEAM:MLSS

US$61.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Accelerate Diagnostics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.88
52 Haftanın En Yüksek Seviyesi	US$6.25
52 Haftanın En Düşük Seviyesi	US$0.73
Beta	0.62
11 Aylık Değişim	9.94%
3 Aylık Değişim	41.35%
1 Yıllık Değişim	-68.87%
33 Yıllık Değişim	-97.02%
5 Yıllık Değişim	-98.81%
Halka arzdan bu yana değişim	17.50%

Son Haberler & Güncellemeler

Recent updates

Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher

Apr 17

Accelerate Diagnostics spikes as Chief Technology Officer raises stake

Aug 30

Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Aug 20

Accelerate Diagnostics jumps 14% after beating Q2 estimates

Aug 15

Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022

Mar 15

Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022

Jan 04

Accelerate Diagnostics: An Investment Assessment

Sep 07

Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?

Feb 20

Accelerate Diagnostics foresees Q4 and FY2020 revenue below consensus

Jan 12

Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three Years

Dec 29

Hissedar Getirileri

	AXDX	US Medical Equipment	US Pazar
7D	5.0%	-0.8%	0.5%
1Y	-68.9%	29.2%	36.8%

Getiri vs. Endüstri: AXDX geçen yıl % 29.2 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: AXDX geçen yıl % 36.8 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is AXDX's price volatile compared to industry and market?
AXDX volatility
AXDX Average Weekly Movement	11.2%
Medical Equipment Industry Average Movement	7.9%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: AXDX hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: AXDX 'nin haftalık oynaklığı ( 11% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1982	134	Jack Phillips	acceleratediagnostics.com

Bir in vitro diagnostik şirketi olan Accelerate Diagnostics, Inc. Amerika Birleşik Devletleri, Avrupa ve Orta Doğu'da ciddi enfeksiyonların teşhisi için çözümler sunmaktadır. Şirket, gram-pozitif ve gram-negatif organizmalar da dahil olmak üzere ciddi veya sağlık hizmetleri ile ilişkili enfeksiyonlarla ilişkili patojenlerin tanımlanması ve antibiyotik duyarlılık testi için bir in vitro tanı platformu olan Accelerate Pheno sistemini sunmaktadır. Ayrıca, yüksek morbidite ve mortalite riski taşıyan ve hayatı tehdit eden bakteriyemi veya fungemi şüphesi olan hastalar için tanımlama ve antibiyotik duyarlılık testi sonuçları sağlayan sistem için bir test kiti olan Accelerate PhenoTest'i de sunmaktadır.

Accelerate Diagnostics, Inc. Temel Bilgiler Özeti

Accelerate Diagnostics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
AXDX temel i̇stati̇sti̇kler
Piyasa değeri	US$43.81m
Kazançlar(TTM)	-US$37.91m
Gelir(TTM)	US$12.23m

3.6x

P/S Oranı

-1.2x

F/K Oranı

AXDX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
AXDX gelir tablosu (TTM)
Gelir	US$12.23m
Gelir Maliyeti	US$10.09m
Brüt Kâr	US$2.14m
Diğer Giderler	US$40.05m
Kazançlar	-US$37.91m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 07, 2024

Hisse başına kazanç (EPS)	-1.60
Brüt Marj	17.49%
Net Kâr Marjı	-309.87%
Borç/Özkaynak Oranı	-117.7%

AXDX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

AXDX Stoklara Genel Bakış

Ödüller

Risk Analizi

Accelerate Diagnostics, Inc. Rakipler

NasdaqGS:APYX

US$43.3m

OTCPK:MDNC

US$58.7m

NasdaqGM:DHAI

US$49.1m

NYSEAM:MLSS

US$61.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? System

Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical Trial

Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq

Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC

Recent updates

Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? System

Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical Trial

Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq

Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC

Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living Trust

Accelerate Diagnostics, Inc. has completed a Composite Units Offering.

Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 15%

Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

CEO, President & Director exercised options and sold US$73k worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Accelerate Diagnostics Submits 510(K) Application to FDA for Gram-Negative Menu Expansion and Breakpoint Updates for the Accelerate Phenotest(R) BC Kit

Accelerate Diagnostics, Inc. Announces Resignation of Ron Price as Chief Commercial Officer

Consensus forecasts updated

Price target decreased to US$2.00

Accelerate Diagnostics, Inc. Provides Earnings Guidance for the Year 2022

Insider recently bought US$80k worth of stock

Accelerate Diagnostics spikes as Chief Technology Officer raises stake

Consensus revenue estimates increase by 10%

Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Accelerate Diagnostics, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Accelerate Diagnostics jumps 14% after beating Q2 estimates

CEO, President & Director exercised options and sold US$26k worth of stock

Consensus forecasts updated

Accelerate Diagnostics Announces Commercialization of its Accelerate Arc System Having Completed IVD Registration with FDA

First quarter 2022 earnings: EPS exceeds analyst expectations

CEO, President & Director exercised options and sold US$82k worth of stock

Price target decreased to US$5.00

Accelerate Diagnostics, Inc., Annual General Meeting, May 12, 2022

Accelerate Diagnostics, Inc. Announces Launch of Accelerate Arc™ Module and BC Kit

Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022

Consensus revenue estimates fall by 14%

Full year 2021 earnings: EPS exceeds analyst expectations

Accelerate Diagnostics, Inc. Elects Wayne C. Burris as Member of the Board

Insider recently bought US$66k worth of stock

Independent Director recently bought US$524k worth of stock

Independent Director recently bought US$196k worth of stock

Accelerate Diagnostics, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Independent Director recently bought US$277k worth of stock

Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022

Independent Director recently bought US$369k worth of stock

Independent Director recently bought US$248k worth of stock

Independent Director recently bought US$606k worth of stock

Accelerate Diagnostics, Inc. Announces New Accelerate Pheno System Multi-Center Study Published in Clinical Infectious Diseases

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)

Accelerate Diagnostics, Inc. announced that it has received $1.55 million in funding

Independent Director recently bought US$150k worth of stock

Price target decreased to US$11.00

Accelerate Diagnostics: An Investment Assessment

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.35 loss in 2Q 2020)

Consensus forecasts updated